Catabasis Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CATB research report →
Companywww.catabasis.com
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD).
- CEO
- Jill Milne
- IPO
- 2015
- Employees
- 20
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $234.86M
- P/E
- 0.00
- P/S
- 332.66
- P/B
- 0.00
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- -15144.33%
- Net Margin
- -13938.24%
- ROE
- -35.71%
- ROIC
- -42.81%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-94,260,000 · 0.00%
- EPS
- $-1.68 · 0.00%
- Op Income
- $-111,558,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $10.26
- 52W Low
- $1.25
- 50D MA
- $8.23
- 200D MA
- $3.74
- Beta
- 1.66
- Avg Volume
- 528.92K
Get TickerSpark's AI analysis on CATB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 21 | Harshbarger Benjamin | other | 200,000 |
| Jun 2, 21 | Callori Fred | other | 85,000 |
| Jun 2, 21 | Violin Jonathan | other | 85,000 |
| Jun 2, 21 | Clauser Noah | other | 600,000 |
| Jun 2, 21 | KISHBAUCH MICHAEL D | other | 100,000 |
| Jun 2, 21 | BATE KENNETH | other | 100,000 |
| Jun 2, 21 | Milne Jill C. | other | 1,400,000 |
| Jun 2, 21 | LAPOINTE ANTHONY GREGG | other | 100,000 |
| Jun 2, 21 | Harshbarger Benjamin | other | 400,000 |
| Feb 1, 21 | PERCEPTIVE ADVISORS LLC | other | 1,617 |
Our CATB Coverage
We haven't published any research on CATB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CATB Report →